Ophthalmic medtech and pharmaceutical company Glaukos Corporation announced on December 15 that the U.S. FDA has approved the iDose TR, a single-administration dose of 75 micrograms (mcg) of travoprost, a prostaglandin analog to treat people with open-angle glaucoma or ocular hypertension. Learn more about what iDose TR is, how it works, and what it could mean for you.*

What is iDose TR?

iDose TR is a long-term, intracameral implant, which means that the medication-release device is injected into the anterior (front) chamber of the eye. The iDose TR delivers continuous (24/7) therapeutic levels of travoprost for extended time periods, lowering and then maintaining internal eye pressure. 

How is iDose an improvement on current treatments?

“We now have a new tool that will confront the standard legacy practice of relying on topical drops, which are known to cause uncomfortable side effects and present a myriad of challenges such as treatment adherence, complex dosing regimens and difficulty with self-administration,” said clinician and researcher John Berdahl, M.D.

“The clinical data suggest that iDose TR is not only effective with a favorable safety profile, but it has potential to relieve patients from the burdens of prescription eye drops for an extended period of time. Dr. Berdahl said.

What it could mean for glaucoma patients

Glaukos has announced its intention to launch the iDose TR commercially in Spring 2024. In addition to the commercial launch, Glaukos has promised that, for each iDose TR that is sold, it will donate a dose to qualified charitable organizations for recipients who meet eligibility criteria.

*Vision Monday Staff. (2023, December 15). Glaukos Announces FDA Approval of iDose TR. Vision Monday. https://www.visionmonday.com/eyecare/article/glaukos-announces-fda-approval-of-idose-tr/?uid=735E5A1D699E4A0DEB33C33AD7F4DC74

Responsum Health closely vets all sources to ensure that we always provide you with high-quality, reliable information. We do not, however, endorse or recommend any specific providers, treatments, or products, and the use of a given source does not imply an endorsement of any provider, treatment, medication, or procedure discussed within.